TY - JOUR
T1 - Artificial Intelligence–Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis
AU - Grogan, Martha
AU - Lopez-Jimenez, Francisco
AU - Cohen-Shelly, Michal
AU - Dispenzieri, Angela
AU - Attia, Zachi I.
AU - Abou Ezzedine, Omar F.
AU - Lin, Grace
AU - Kapa, Suraj
AU - Borgeson, Daniel D.
AU - Friedman, Paul A.
AU - Murphree, Dennis H.
N1 - Funding Information:
Grant Support: This work was funded by Mayo Clinic Department of Cardiovascular Medicine and Mayo Cardiovascular Research Center with no industry support.
Funding Information:
Potential Competing Interests: Martha Grogan receives research (clinical trial) grant support from Alnylam , Eidos , Pfizer , and Prothena and consulting fees and honoraria (paid to Mayo Clinic, no personal compensation) from Akcea, Alnylam, Eidos, Pfizer, and Prothena. Zachi Attia has served as an advisor to AliveCor. Angela Dispenzieri receives research support from Celgene , Takeda , Janssen , Pfizer , and Alnylam and is on the advisory board for Janssen. Suraj Kapa has served on an advisory board for Pfizer. Grace Lin receives research funding from Ionis and Pfizer . Omar Abou Ezzedine receives research funding from Pfizer . The remaining authors have nothing to disclose. Drs Grogan, Lopez-Jimenez, Dispenzieri, Attia, Abou Ezzedine, Kapa, Friedman, and Murphree and Mayo Clinic have licensed the algorithm described in this work to Anumana and may benefit from its commercialization.
Funding Information:
Grant Support: This work was funded by Mayo Clinic Department of Cardiovascular Medicine and Mayo Cardiovascular Research Center with no industry support.Potential Competing Interests: Martha Grogan receives research (clinical trial) grant support from Alnylam, Eidos, Pfizer, and Prothena and consulting fees and honoraria (paid to Mayo Clinic, no personal compensation) from Akcea, Alnylam, Eidos, Pfizer, and Prothena. Zachi Attia has served as an advisor to AliveCor. Angela Dispenzieri receives research support from Celgene, Takeda, Janssen, Pfizer, and Alnylam and is on the advisory board for Janssen. Suraj Kapa has served on an advisory board for Pfizer. Grace Lin receives research funding from Ionis and Pfizer. Omar Abou Ezzedine receives research funding from Pfizer. The remaining authors have nothing to disclose. Drs Grogan, Lopez-Jimenez, Dispenzieri, Attia, Abou Ezzedine, Kapa, Friedman, and Murphree and Mayo Clinic have licensed the algorithm described in this work to Anumana and may benefit from its commercialization.
Publisher Copyright:
© 2021 Mayo Foundation for Medical Education and Research
PY - 2021/11
Y1 - 2021/11
N2 - Objective: To develop an artificial intelligence (AI)–based tool to detect cardiac amyloidosis (CA) from a standard 12-lead electrocardiogram (ECG). Methods: We collected 12-lead ECG data from 2541 patients with light chain or transthyretin CA seen at Mayo Clinic between 2000 and 2019. Cases were nearest neighbor matched for age and sex, with 2454 controls. A subset of 2997 (60%) cases and controls were used to train a deep neural network to predict the presence of CA with an internal validation set (n=999; 20%) and a randomly selected holdout testing set (n=999; 20%). We performed experiments using single-lead and 6-lead ECG subsets. Results: The area under the receiver operating characteristic curve (AUC) was 0.91 (CI, 0.90 to 0.93), with a positive predictive value for detecting either type of CA of 0.86. By use of a cutoff probability of 0.485 determined by the Youden index, 426 (84%) of the holdout patients with CA were detected by the model. Of the patients with CA and prediagnosis electrocardiographic studies, the AI model successfully predicted the presence of CA more than 6 months before the clinical diagnosis in 59%. The best single-lead model was V5 with an AUC of 0.86 and a precision of 0.78, with other single leads performing similarly. The 6-lead (bipolar leads) model had an AUC of 0.90 and a precision of 0.85. Conclusion: An AI-driven ECG model effectively detects CA and may promote early diagnosis of this life-threatening disease.
AB - Objective: To develop an artificial intelligence (AI)–based tool to detect cardiac amyloidosis (CA) from a standard 12-lead electrocardiogram (ECG). Methods: We collected 12-lead ECG data from 2541 patients with light chain or transthyretin CA seen at Mayo Clinic between 2000 and 2019. Cases were nearest neighbor matched for age and sex, with 2454 controls. A subset of 2997 (60%) cases and controls were used to train a deep neural network to predict the presence of CA with an internal validation set (n=999; 20%) and a randomly selected holdout testing set (n=999; 20%). We performed experiments using single-lead and 6-lead ECG subsets. Results: The area under the receiver operating characteristic curve (AUC) was 0.91 (CI, 0.90 to 0.93), with a positive predictive value for detecting either type of CA of 0.86. By use of a cutoff probability of 0.485 determined by the Youden index, 426 (84%) of the holdout patients with CA were detected by the model. Of the patients with CA and prediagnosis electrocardiographic studies, the AI model successfully predicted the presence of CA more than 6 months before the clinical diagnosis in 59%. The best single-lead model was V5 with an AUC of 0.86 and a precision of 0.78, with other single leads performing similarly. The 6-lead (bipolar leads) model had an AUC of 0.90 and a precision of 0.85. Conclusion: An AI-driven ECG model effectively detects CA and may promote early diagnosis of this life-threatening disease.
UR - http://www.scopus.com/inward/record.url?scp=85109040226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109040226&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2021.04.023
DO - 10.1016/j.mayocp.2021.04.023
M3 - Article
C2 - 34218880
AN - SCOPUS:85109040226
SN - 0025-6196
VL - 96
SP - 2768
EP - 2778
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 11
ER -